Heron Therapeutics, Inc. (HRTX)

2.5500 +0.2100 (+8.97%) 收市：04:00PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 126

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Craig Alexander Collard	CEO & Director	無	無	1966
Ms. Ira Duarte	Executive VP & CFO	無	無	1969
Mr. Ryan Craig	Vice President of Marketing	無	無	無
Mr. Sean T. Ristine	Senior Vice President of Human Resources	無	無	1970
Mr. Robert Sullivan	Senior VP of Oncology Care Franchise & Commercial Operations	無	無	1978
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer	無	無	1962
Jeff Cohn	Executive Director, Assistant General Counsel & Assistant Secretary	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

公司管治

截至 2024年5月1日 止，Heron Therapeutics, Inc. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：8；董事會：4；股東權利：1；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。